Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more
Nyrada Inc (NYR) - Net Assets
Latest net assets as of December 2025: AU$9.84 Million AUD
Based on the latest financial reports, Nyrada Inc (NYR) has net assets worth AU$9.84 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$10.39 Million) and total liabilities (AU$548.97K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$9.84 Million |
| % of Total Assets | 94.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | -75.32% |
| 10-Year Change | N/A |
| Growth Volatility | 78.71 |
Nyrada Inc - Net Assets Trend (2018–2025)
This chart illustrates how Nyrada Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nyrada Inc (2018–2025)
The table below shows the annual net assets of Nyrada Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$3.58 Million | -29.19% |
| 2024-06-30 | AU$5.05 Million | +18.63% |
| 2023-06-30 | AU$4.26 Million | -62.97% |
| 2022-06-30 | AU$11.50 Million | -20.65% |
| 2021-06-30 | AU$14.49 Million | +162.22% |
| 2020-06-30 | AU$5.53 Million | +211.55% |
| 2019-06-30 | AU$-4.95 Million | -263.59% |
| 2018-06-30 | AU$-1.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nyrada Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2716026700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$29.77 Million | 832.18% |
| Other Comprehensive Income | AU$3.39 Million | 94.67% |
| Total Equity | AU$3.58 Million | 100.00% |
Nyrada Inc Competitors by Market Cap
The table below lists competitors of Nyrada Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vente Unique.com
PA:ALVU
|
$35.59 Million |
|
Caladrius Biosciences Inc.
LSE:0HS8
|
$35.60 Million |
|
Kafein Yazilim
IS:KFEIN
|
$35.62 Million |
|
Tetratherix Ltd
AU:TTX
|
$35.63 Million |
|
BANGO PLC LS-20
F:B1O
|
$35.58 Million |
|
BIOMED-LUBLIN WYT.SUR.
F:6NQ
|
$35.57 Million |
|
Jetpak Top Holding AB
ST:JETPAK
|
$35.56 Million |
|
Optomed PLC
HE:OPTOMED
|
$35.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nyrada Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,051,630 to 3,577,011, a change of -1,474,619 (-29.2%).
- Net loss of 4,845,671 reduced equity.
- Share repurchases of 253,944 reduced equity.
- New share issuances of 3,445,466 increased equity.
- Other comprehensive income decreased equity by 2,013,517.
- Other factors increased equity by 2,193,047.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.85 Million | -135.47% |
| Share Repurchases | AU$253.94K | -7.1% |
| Share Issuances | AU$3.45 Million | +96.32% |
| Other Comprehensive Income | AU$-2.01 Million | -56.29% |
| Other Changes | AU$2.19 Million | +61.31% |
| Total Change | AU$- | -29.19% |
Book Value vs Market Value Analysis
This analysis compares Nyrada Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 29.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | AU$-0.01 | AU$0.53 | x |
| 2019-06-30 | AU$-0.05 | AU$0.53 | x |
| 2020-06-30 | AU$0.05 | AU$0.53 | x |
| 2021-06-30 | AU$0.12 | AU$0.53 | x |
| 2022-06-30 | AU$0.07 | AU$0.53 | x |
| 2023-06-30 | AU$0.03 | AU$0.53 | x |
| 2024-06-30 | AU$0.03 | AU$0.53 | x |
| 2025-06-30 | AU$0.02 | AU$0.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nyrada Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -135.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -202.18%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.48x
- Recent ROE (-135.47%) is below the historical average (-63.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -59077.65% | 0.00x | 0.00x | AU$-2.28 Million |
| 2019 | 0.00% | -841.97% | 0.43x | 0.00x | AU$-3.60 Million |
| 2020 | -104.47% | -513.03% | 0.18x | 1.13x | AU$-6.33 Million |
| 2021 | -24.33% | -150.95% | 0.15x | 1.05x | AU$-4.98 Million |
| 2022 | -34.55% | -363.28% | 0.09x | 1.04x | AU$-5.12 Million |
| 2023 | -183.55% | -546.63% | 0.28x | 1.21x | AU$-8.24 Million |
| 2024 | -27.44% | -42.76% | 0.55x | 1.17x | AU$-1.89 Million |
| 2025 | -135.47% | -202.18% | 0.45x | 1.48x | AU$-5.20 Million |
Industry Comparison
This section compares Nyrada Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nyrada Inc (NYR) | AU$9.84 Million | 0.00% | 0.06x | $35.58 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |